Medical Director/Global Medical Indication Lead - Nephrology(FSP)
Thermo Fisher ScientificSalary not specified
- Full Time
- Junior (1 to 2 years)
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries
Requirements
The Senior Director, Program Management requires a Bachelor’s degree in a related field, along with 10+ years of experience in program management, preferably in the pharmaceutical or biotechnology industry. Strong leadership and influencing skills are essential, as is the ability to work effectively in a cross-functional matrix environment. Experience with drug development programs and a deep understanding of the rare disease space are highly desirable.
Responsibilities
This role involves leading cross-functional teams to drive the execution of drug development programs, facilitating strategic discussions, developing and maintaining program strategy documents such as the Target Product Profile and Clinical Development Plan, ensuring alignment of non-clinical, clinical, regulatory, and commercial strategies, and optimizing for quality, speed, and cost. The Senior Director will also be responsible for creating and maintaining detailed cross-functional plans, inspiring efficient plans to achieve development strategy, and accountable for the overall success of the program.
Skills
Program Management
Cross-functional Collaboration
Project Planning
Risk Management
Agile Methodology
Drug Development
Stakeholder Engagement
Dyno Therapeutics
Develops AI-optimized gene therapy vectors
About Dyno Therapeutics
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.
Watertown, MassachusettsHeadquarters
2018Year Founded
$106MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
51-200Employees